Insider Selling: Sight Sciences (NASDAQ:SGHT) CEO Sells 11,870 Shares of Stock

Sight Sciences, Inc. (NASDAQ:SGHT) CEO Paul Badawi sold 11,870 shares of the firm’s stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $7.48, for a total value of $88,787.60. Following the transaction, the chief executive officer directly owned 5,925,276 shares in the company, valued at $44,321,064.48. This trade represents a 0.20% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Paul Badawi also recently made the following trade(s):

• On Friday, January 2nd, Paul Badawi sold 25,356 shares of Sight Sciences stock. The stock was sold at an average price of $7.43, for a total value of $188,395.08.

Sight Sciences Trading Down 3.1%

SGHT stock traded down $0.24 during trading on Tuesday, hitting $7.47. 197,717 shares of the company traded hands, compared to its average volume of 290,394. The company has a 50-day moving average of $7.52 and a 200-day moving average of $5.13. The company has a debt-to-equity ratio of 0.62, a quick ratio of 8.93 and a current ratio of 9.60. Sight Sciences, Inc. has a 1 year low of $2.03 and a 1 year high of $9.24. The firm has a market capitalization of $394.94 million, a PE ratio of -8.30 and a beta of 2.42.

Sight Sciences (NASDAQ:SGHT) last announced its quarterly earnings data on Wednesday, September 8th. The company reported ($0.81) earnings per share for the quarter. Sight Sciences had a negative net margin of 60.63% and a negative return on equity of 61.59%. The company had revenue of $12.54 million during the quarter. Analysts predict that Sight Sciences, Inc. will post -0.99 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have commented on SGHT. Piper Sandler set a $9.00 price objective on shares of Sight Sciences in a report on Monday. Morgan Stanley upped their price target on Sight Sciences from $6.00 to $8.00 and gave the stock an “equal weight” rating in a research note on Tuesday, December 2nd. UBS Group increased their price objective on Sight Sciences from $7.00 to $12.00 and gave the stock a “buy” rating in a report on Tuesday, December 23rd. Lake Street Capital boosted their target price on shares of Sight Sciences from $5.00 to $7.00 and gave the company a “buy” rating in a report on Tuesday, October 21st. Finally, Wall Street Zen raised shares of Sight Sciences from a “sell” rating to a “hold” rating in a research report on Saturday, September 13th. Four analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $8.30.

Institutional Investors Weigh In On Sight Sciences

Several institutional investors have recently added to or reduced their stakes in SGHT. BNP Paribas Financial Markets lifted its position in Sight Sciences by 99.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 7,579 shares of the company’s stock worth $26,000 after acquiring an additional 3,785 shares during the period. CWM LLC raised its holdings in shares of Sight Sciences by 70.2% during the second quarter. CWM LLC now owns 7,607 shares of the company’s stock worth $31,000 after purchasing an additional 3,137 shares during the last quarter. Tower Research Capital LLC TRC lifted its position in Sight Sciences by 32.7% during the second quarter. Tower Research Capital LLC TRC now owns 11,665 shares of the company’s stock valued at $48,000 after purchasing an additional 2,875 shares during the period. Bank of Montreal Can acquired a new stake in Sight Sciences during the 2nd quarter worth about $49,000. Finally, R Squared Ltd acquired a new stake in Sight Sciences during the 3rd quarter worth about $64,000. Institutional investors and hedge funds own 55.51% of the company’s stock.

More Sight Sciences News

Here are the key news stories impacting Sight Sciences this week:

• Positive Sentiment: Piper Sandler upgraded Sight Sciences to Overweight (from Neutral), a buy-side analyst upgrade that can attract investor interest and buying momentum. Piper Sandler upgrade
• Neutral Sentiment: Despite recent sales, insiders still hold large positions — CEO Paul Badawi (~5.9M shares) and CTO David Badawi (~1.9M shares) retain substantial ownership, which can indicate alignment with long-term value even as they trim stakes. Insider ownership filing
• Negative Sentiment: Clustered insider selling by executives — CEO Paul Badawi, CTO David Badawi, CFO James Rodberg, EVP Brenton Taylor and insider Jeremy Hayden — over Jan. 2–6. Combined disclosed sales total roughly $0.48M across these transactions; each sale was a small percentage (<1%) of the seller’s holdings but the concentrated timing can create downward pressure on the stock. See CEO / executive filings. CEO sale filing CTO sale filing Other insider filings

About Sight Sciences

Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company’s flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye’s natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.

Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.